(Q39585767)

13 September 2017

title

Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials (English)

1 reference

idiopathic pulmonary fibrosis

13 September 2017

main subject

phase III clinical trial

0 references

pulmonary fibrosis

1 reference

based on heuristic

inferred from title

1 reference

3

Luca Richeldi

1 reference

13 September 2017

Roland M du Bois

1

1 reference

13 September 2017

Steven D Nathan

series ordinal

2

1 reference

13 September 2017

Marvin I Schwarz

series ordinal

4

1 reference

13 September 2017

Paul W Noble

series ordinal

5

1 reference

13 September 2017

language of work or name

English

0 references

publication date

12 July 2012

1 reference

American Journal of Respiratory and Critical Care Medicine

13 September 2017

published in

1 reference

13 September 2017

volume

186

1 reference

13 September 2017

issue

8

1 reference

13 September 2017

page(s)

712-715

1 reference

Idiopathic pulmonary fibrosis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

The rising incidence of idiopathic pulmonary fibrosis in the U.K

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Strategies for treating idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Treatment of pulmonary arterial hypertension with targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201206-1010PP

10.1164/RCCM.201206-1010PP

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference